Jazz Pharmaceutical (Nasdaq: JAZZ) – is a biopharmaceutical company that develops and sells pharmaceutical products internationally. The company’s products primarily treat patients in three areas: sleep disorders, hematology, and oncology. The company was founded in 2003 and is headquartered in Dublin, Ireland.

The first thing that stood out to me about Jazz was its fundamental performance. The company has seen earnings grow by 12% per year over the last three years and they grew by 23% in the fourth quarter of 2018.

Jazz is expected to report first quarter earnings on May 7, so be prepared for that.

Jazz’s sales have grown at a rate of 13% per year over the last three years and they grew by 9% in the most recent quarterly report.

Analysts expect sales to grow by 4.8% in the first quarter.

The management efficiency measurements are especially strong for Jazz.

The return on equity is 30.7%, the profit margin is 52.3%, and the operating margin is at 37.9%.

The sentiment picture for Jazz is mixed with analysts rather bullish on the stock while short sellers are rather bearish.

There are 19 analysts following the stock currently and 15 have the stock rated as a “buy” while the other four rate the stock as a “hold”. The short interest ratio is currently at 4.87 and it has risen from 2.0 since mid-December. There were 2.34 million shares sold short as of April 15.

The weekly chart shows that the stock did well in the first half of 2017 and then slipped back a little. The stock did the same thing in 2018, rose in the first half and then slipped in the second half. Even though it has happened for two straight years, I don’t believe this is a seasonal pattern in the stock.

What we see over the last four months is that the stock has formed a short-term trend channel with the upper rail connecting the highs from February and April. The lower rail connects the lows from December, February, and last week.

The overbought/oversold indicators had slipped in to oversold territory back in December and it was the first time since late 2016 that both were that low. The rally off of that low took the weekly stochastic readings up to overbought territory, but not the RSI. The pullback in the last few weeks brought the stochastics back down and they are near the midway point at this time.

Suggested strategy: Buy JAZZ with a maximum entry price of $133.00. I would set a target of at least $170.00 over the next 6 to 9 months (for a potential 30% return from here). I would also suggest a stop at $123.00.

— Rick Pendergraft

Nvidia's Secret Partner... This Is The New AI Chip Powerhouse [sponsor]
I bet you've never heard of it... but this newly public company is set to become key to Nvidia's seat on the AI throne. And for now... you can get in while it's still cheap. Details Here! Find Out What It Is Right Here.